Insulin signalling in hepatocytes of humans with type 2 diabetes: Excessive production and activity of protein kinase C-ι (PKC-ι) and dependent processes and reversal by PKC-ι inhibitors

Diabetologia

Volumn 55, Issue 5, 2012, Pages 1446-1457

  Sajan, M P ^a   Farese, R V ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ROSKAMP INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Hepatocytes; Protein kinase C iota; Type 2 diabetes

Indexed keywords

CARBOHYDRATE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LIPID; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; FEMALE; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; LIVER CELL; MALE; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITIVE FEEDBACK; PRIORITY JOURNAL;

ADULT; AGED; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; ISOENZYMES; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84862587760     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2477-5     Document Type: Article

References (21)

1. Standaert ML, Sajan MP, Miura A et al (2004) Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic ob/ob and Goto-Kakizaki liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high fat-induced insulin-resistant states. J Biol Chem 279: 24929-24934
2. Sajan MP, Standaert ML, Nimal S et al (2009) Critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFκB in obesity. J Lipid Res 50: 1133-1145
3. Sajan MP, Standaert ML, Rivas J et al (2009) Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as model of diabetes, and relationships to hyperlipidaemia and insulin resistance. Diabetologia 52: 1197-1207
4. Valverde AM, Burks DJ, Fabregat I et al (2003) Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes 52: 2239-2248
5. Ueki K, Yamauchi T, Tamemoto H et al (2000) Restored insulinsensitivity in IRS-1-deficient mice treated by adenovirus-mediated gene therapy. J Clin Invest 105: 1437-1445
6. Sajan MP, Standaert ML, Miura A, Farese RV (2004) Tissuespecific differences in activation of atypical protein kinase C and protein kinase B in muscle, liver and adipocytes of insulin receptor substrate-1 knockout mice. Mol Endocrinol 18: 2513-2521
7. Guo S, Copps KD, Park S et al (2009) The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 29: 5070-5083
8. Farese RV, Sajan MP (2010) Metabolic functions of atypical protein kinase C: "good and bad" as defined by nutritional status. Am J Physiol Endocrinol Metab 298: E385-E394
9. Matsumoto M, Ogawa W, Akimoto K et al (2003) PKCλ in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 112: 935-944
10. Farese RV, Sajan MP, Yang H et al (2007) Muscle-specific knockout of protein kinase C-λ impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 117: 2289-2301
11. Beeson M, Sajan MP, Dizon M et al (2003) Activation of protein kinase C-ζ by insulin and phosphatidylinositol-3, 4, 5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose intolerance. Amelioration by rosiglitazone and exercise. Diabetes 52: 1926-1934
12. Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, Fields AP (2006) A novel small molecule inhibitor of protein kinase Cι blocks transformed growth of non-small cell lung cancer. Cancer Res 66: 1767-1774
13. Erdogan E, Lamark T, Stallings-Mann M et al (2006) Aurothiomalate inhibits transformed growth by targeting the PB1 domain of atypical protein kinase Ciota. J Biol Chem 281: 28450-28459
14. Fields AP, Frederick LA, Regala RP (2007) Targeting the oncogenic protein kinase Ciota for the treatment of cancer. Biochem Soc Trans 23: 1996-2000
15. Regala RP, Thompson EA, Fields AP (2008) Atypical protein kinase Cι expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res 68: 5888-5895
16. Pillai P, Desai S, Patel R, Sajan MP, Farese RV, Acevedo-Duncan M (2011) ICA-1: a novel PKC-ι inhibitor that abrogates cell proliferation and induces apoptosis in neuroblastoma. Int J Biochem Cell Biol 43: 784-794
17. Standaert ML, Galloway L, Bandyopadhyay G, Moscat J, Farese RV (1997) PKC-i as a downstream effector of PI 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem 272: 30075-30082
18. Sajan MP, Bandyopadhyay G, Miura A (2010) AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-and PDK1-dependent activation of atypical PKC. Am J Physiol Endocrinol Metab 298: E179-E192
19. Kim Y-B, Kotani K, Ciaraldi TP, Henry RR, Kahn BB (2003) Insulin-stimulated protein kinase C-λ/i activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes; reversal with weight reduction. Diabetes 52: 1935-1942
20. Fleischmann M, Iynedjian PB (2000) Regulation of sterol regulatory element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J 349: 13-17
21. Li S, Brown MS, Goldstein JL (2010) Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluceoneogenesis. Proc Natl Acad Sci USA 107: 3441-3446